Application Serial No. 09/977,406

Amendment Dated: February 22, 2005

AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-183 (Canceled).

- 184. (New) A polypeptide of from five to 64 amino acids that inhibits the growth of a tumor cell or inhibits the growth of prostatic adenocarcinoma, wherein at least five contiguous amino acids of said polypeptide are identical to five contiguous amino acids of SEQ ID NO: 5.
- 185. (New) The polypeptide of claim 184, wherein said polypeptide comprises the amino acid sequence defined in SEQ ID NO.:5.
- 186. (New) The polypeptide of claim 184, wherein said polypeptide consists of the amino acid sequence defined in SEQ ID NO.:5
- 187. (New) The polypeptide of claim 184, wherein said polypeptide comprises amino acids no.1 to 6 of SEQ ID NO.:5.
- 188. (New) The polypeptide of claim 184, wherein said polypeptide is as defined in any one of SEQ ID NOS.:10 to 88.
- 189. (New) The polypeptide of claim 184, wherein said polypeptide is as defined in any one of SEQ ID NO.: 90, SEQ ID NO.: 91 and SEQ ID NO.: 92.
- 190. (New) The polypeptide of claim 184, wherein said polypeptide has at least 50% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

Application Serial No. 09/977,406

Amendment Dated: February 22, 2005

191. (New) The polypeptide of claim 190, wherein said polypeptide has at least 70% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

- 192. (New) The polypeptide of claim 191, wherein said polypeptide has at least 80% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.
- 193. (New) The polypeptide of claim 192, wherein said polypeptide has at least 90% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.
 - 194. (New) A pharmaceutical composition comprising:
 - a) the polypeptide of claim 184; and
- b) at least one of an anticancer drug and a pharmaceutically acceptable carrier.
- 195. (New) The pharmaceutical composition of claim 194, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.
- 196. (New) The pharmaceutical composition of claim 194, further comprising a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of the composition.
- 197. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 194.
- 198. (New) A polypeptide which inhibits the growth of a tumor cell or inhibits the growth of prostatic adenocarcinoma, said polypeptide having at least 40% of its

Application Serial No. 09/977,406

Amendment Dated: February 22, 2005

amino acid sequence being identical to the amino acid sequence defined in SEQ ID NO.:5.

- 199. (New) The polypeptide of claim 198, wherein said polypeptide has at least 50% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.
- 200. (New) The polypeptide of claim 199, wherein said polypeptide has at least 70% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.
- 201. (New) The polypeptide of claim 200, wherein said polypeptide has at least 80% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.
- 202. (New) The polypeptide of claim 201, wherein said polypeptide has at least 90% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.
 - 203. (New) A pharmaceutical composition comprising:
 - a) the polypeptide of claim 198; and
 - b) at least one of an anticancer drug and a pharmaceutical carrier.
- 204. (New) The pharmaceutical composition of claim 203, wherein said composition comprises an anticancer drug selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.
- 205. (New) The pharmaceutical composition of claim 203, further comprising a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of the composition.

Atty. Dkt. No. CLWZ 200147 Application Serial No. 09/977,406

Amendment Dated: February 22, 2005

206. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 203.

- 207. (New) A pharmaceutical composition comprising;
- a) a polypeptide consisting of the amino acid sequence defined in SEQ ID NO.:5, and
 - b) at least one of an anticancer drug and a pharmaceutical carrier.
- 208. (New) The pharmaceutical composition of claim 207 wherein the polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.
- 209. (New) The pharmaceutical composition of claim 207, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.
- 210. (New) The pharmaceutical composition of claim 207, further comprising a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of the composition.
- 211. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 207.
 - (New) A pharmaceutical composition comprising;
 - a) the polypeptide of claim 187; and
- b) at least one of an anticancer drug and a pharmaceutically acceptable carrier.

Application Serial No. 09/977,406

Amendment Dated: February 22, 2005

213. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 212.

- 214. (New) A pharmaceutical composition comprising:
- a) a polypeptide comprising SEQ ID NO.:5 provided that said polypeptide is not as defined in SEQ ID NO.:1, and
- b) at least one of an anticancer drug and a pharmaceutically acceptable carrier.
- 215. (New) The pharmaceutical composition of claim 214 wherein the polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.
- 216. (New) The pharmaceutical composition of claim 214, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.
- 217. (New) The pharmaceutical composition of claim 214 further comprising a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of the composition.
- 218. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 214.
- 219. (New) A polypeptide comprising at least two repetitions of the amino acid sequence defined in SEQ ID NO.:5.
 - 220. (New) A pharmaceutical composition comprising:
 - a) the polypeptide of claim 219, and

Atty. Dkt. No. CLWZ 200147 Application Serial No. 09/977,406

Amendment Dated: February 22, 2005

b) at least one of an anticancer drug and a pharmaceutically acceptable carrier.

- 221. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 220.
 - 222. (New) A pharmaceutical composition comprising;
 - a) the polypeptide of claim 185; and
- b) at least one of an anticancer drug and a pharmaceutically acceptable carrier.
- 223. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 222.